Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Regeneron Partners NGF Antibody With Teva To Mitigate Risks

Executive Summary

Regeneron and Teva will partner on the development and commercialization of the late-stage nerve growth factor antibody fasinumab for pain in a deal that will help Regeneron fund a 10,000-patient safety database.


Related Content

CNS Licensing Trends: Volume Falls, Values Rise
Biopharma Quarterly Dealmaking Statistics, Q3 2016
Regeneron’s Fasinumab Brings Second Clinical Hold For Anti-NGF Class
Deal Watch: Allergan Deal-Binge Includes Derm, NASH Buys
2016 Pharma Dealmaking: Waiting On The High-Value Deals
Regeneron Revives NGF Inhibitor With Phase II/III Data; Safety Issue Remains
US FDA panel: Let anti-NGF studies move forward, despite 'severe' joint risks
Pfizer suspends worldwide studies for tanezumab in osteoarthritis


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts